Latest news with #DrReddys
Time of India
18 hours ago
- Business
- Time of India
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories maintains a low beta value
29 Jul 2025 | 09:16:58 AM IST Stay up-to-date with the Dr Reddys Stock Liveblog, your trusted source for real-time updates and thorough analysis of a prominent stock. Explore the latest details on Dr Reddys, including: Last traded price 1289.1, Market capitalization: 107444.06, Volume: 30455, Price-to-earnings ratio 18.91, Earnings per share 68.07. Get a comprehensive understanding of Dr Reddys with our coverage of both fundamental and technical indicators. Stay informed about breaking news that can have a significant impact on Dr Reddys's performance. Our expert opinions and recommendations empower you to make well-informed investment choices. Trust the Dr Reddys Stock Liveblog to keep you informed and equipped in the dynamic market landscape. The data points are updated as on 09:16:58 AM IST, 29 Jul 2025 Show more
Time of India
5 days ago
- Business
- Time of India
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories showcases robust returns
25 Jul 2025 | 09:08:28 AM IST Discover the Dr Reddys Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent stock. Keep track of Dr Reddys with the latest details, including: Last traded price 1266.0, Market capitalization: 105616.32, Volume: 3981, Price-to-earnings ratio 18.59, Earnings per share 68.07. Our comprehensive coverage combines fundamental and technical indicators to provide you with a comprehensive view of Dr Reddys's performance. Stay informed about breaking news that can sway Dr Reddys's trajectory in the market. With our expert insights and stock recommendations, make well-informed financial decisions. Join us on this journey as we explore the exciting potential of Dr Reddys. The data points are updated as on 09:08:27 AM IST, 25 Jul 2025 Show more
Time of India
6 days ago
- Business
- Time of India
Dr Reddys Share Price Live Updates: Dr. Reddys Trading Strongly Above R3
Stay updated with the Dr Reddys Stock Liveblog, your one-stop destination for real-time information and analysis of a leading stock. Explore the latest updates on Dr Reddys stock, including: Last traded price 1286.6, Market capitalization: 104105.73, Volume: 696974, Price-to-earnings ratio 18.33, Earnings per share 68.07. Our liveblog combines fundamental and technical insights to offer a comprehensive overview of Dr Reddys's performance. Gain valuable market knowledge and make informed decisions with our expert analysis. Be the first to know about breaking news that can impact Dr Reddys's trajectory. Join us on this journey as we explore the exciting potential of Dr Reddys. The data points are updated as on 09:27:54 AM IST, 24 Jul 2025 Show more Show less
Bloomberg
6 days ago
- Business
- Bloomberg
Dr Reddy's Joins Generic Drugmakers Readying Semaglutide Launch
India's Dr Reddy's Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo Nordisk A/S's blockbuster weight-loss drug Wegovy — next year, joining companies including Biocon Ltd. and Sandoz Group AG. The Hyderabad-based pharmaceutical company is readying 87 countries including core markets such as Canada, Brazil, and India as patents for the drug begin to expire globally, Chief Executive Officer Erez Israeli said Wednesday. A key part of the strategy is targeting countries where Novo Nordisk does not hold patents for semaglutide, he said.
Reuters
6 days ago
- Business
- Reuters
India's Dr Reddy's plans to launch generic obesity drugs in 87 countries next year, CEO says
HYDERABAD July 23 (Reuters) - Dr Reddy's Laboratories ( opens new tab plans to launch a cheaper copycat version of Novo Nordisk's ( opens new tab blockbuster weight-loss drug Wegovy in 87 countries next year, the Indian drugmaker's CEO, Erez Israeli, said on Wednesday. Drugmakers are racing to get a share of the global obesity drug market, expected to generate around $150 billion in sales by the early 2030s, after Denmark-based Novo and its U.S. rival Eli Lilly (LLY.N), opens new tab saw extraordinary demand for their medicines. Dr Reddy's initially plans to launch the generic version of semaglutide - the active ingredient of Novo's Wegovy and diabetes medicine Ozempic - in Canada, India, Brazil, Turkey and other emerging markets, subject to patent expiry, Israeli said. "U.S. and Europe will open later... (and) all the other Western markets will be open between 2029 to 2033," Israeli said a press conference to discuss the company's earnings. He expects the generic drug to generate 'hundreds of millions of dollars' in sales for the company. Semaglutide's patent is expected to expire in several countries next year, including in India in March. Novo Nordisk had sued Dr Reddy's in May alleging patent infringement of semaglutide, according to documents seen by Reuters. Dr Reddy's has filed relevant regulatory applications in all the countries it is planning to launch the generic version in, Israeli said. Other Indian drugmakers, including Cipla ( opens new tab, Lupin ( opens new tab, Biocon ( opens new tab, Sun Pharma ( opens new tab, also plan to launch these generic weight-loss drugs after Novo's and Lilly's success. Novo launched Wegovy in India last month, following Lilly's Mounjaro launch for weight-loss and diabetes management. The drugs belong to a class called GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer. Dr Reddy's also aims to launch 26 GLP-1 drugs within the next decade, Israeli said.
